Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02718898
Registration number
NCT02718898
Ethics application status
Date submitted
21/03/2016
Date registered
24/03/2016
Date last updated
16/09/2019
Titles & IDs
Public title
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
Query!
Scientific title
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis
Query!
Secondary ID [1]
0
0
I1F-MC-RHBQ
Query!
Secondary ID [2]
0
0
16010
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IXORA-Q
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Genital Psoriasis
0
0
Query!
Psoriasis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ixekizumab
Treatment: Drugs - Placebo
Experimental: Ixekizumab - Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.
Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40.
Placebo Comparator: Placebo - Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.
Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40.
Treatment: Drugs: Ixekizumab
Administered SC
Treatment: Drugs: Placebo
Administered SC
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)
Query!
Assessment method [1]
0
0
sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe.
sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Number of Participants Achieving Overall sPGA (0,1)
Query!
Assessment method [1]
0
0
The overall sPGA is the physician's global assessment of the participant's psoriasis (Ps) lesions at a given time point. Plaques were assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity was given using the anchors of 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe.
Overall sPGA (0,1) : An overall sPGA assessed as either 0 or 1.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Number of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS)
Query!
Assessment method [2]
0
0
GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (= no severity) and 10 (worst imaginable severity).
Query!
Timepoint [2]
0
0
Week 12
Query!
Secondary outcome [3]
0
0
Number of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2
Query!
Assessment method [3]
0
0
The SFQ is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual frequency. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Respondents were asked to answer the questions based on their psoriasis symptoms in the genital area. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with the following response options: 0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = always.
*The SFQ is also referred to as the GenPs-SFQ (genital psoriasis sexual frequency questionnaire).
Query!
Timepoint [3]
0
0
Week 12
Query!
Secondary outcome [4]
0
0
Number of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS)
Query!
Assessment method [4]
0
0
GPSIS is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual activity.
The GPSIS Sexual Activity Avoidance Subscale includes 2 items:
Item 1 asks whether the participant has been sexually active in the past week. (No due to other reasons = 1, No due to genital Ps = 5) Item 2 asks how often the participant avoided sexual activity in the past week due to Genital Psoriasis. (Never = 1, rarely = 2, Sometimes = 3, Often = 4)
Query!
Timepoint [4]
0
0
Week 12
Query!
Secondary outcome [5]
0
0
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
Query!
Assessment method [5]
0
0
DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: 1) Symptoms and feelings 2) Daily activities 3) Leisure 4) Work and school 5) Personal relationships 6) Treatment.
Response categories include:
0 = not at all; 1 = a little; 2 = a lot; 3 = very much; "not relevant" responses scored as "0" and total score range of 0 to 30; higher scores indicate poor quality of life.
Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, baseline body surface area (BSA) category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
Query!
Timepoint [5]
0
0
Baseline, Week 12
Query!
Secondary outcome [6]
0
0
Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score
Query!
Assessment method [6]
0
0
mGPASI determines participants psoriasis severity in the genital region at a given time point yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. scoring index incorporates the degree of erythema (or redness), induration (or thickness), and scaling) of the genital plaques as well as erosion, fissure, and/or ulcer as a product of the genital area involved. LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
Query!
Timepoint [6]
0
0
Baseline, Week 12
Query!
Secondary outcome [7]
0
0
Number of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital)
Query!
Assessment method [7]
0
0
Patient's Global Assessment of Genital Psoriasis (PatGA-Genital) is a participant-administered, single-item scale on which participants are asked to rank the severity of their genital psoriasis "today" by circling a number on a 0 to 5 NRS, as follows: from 0 (clear), no genital psoriasis; to 5 (severe).
Query!
Timepoint [7]
0
0
Week 12
Query!
Secondary outcome [8]
0
0
Change From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS)
Query!
Assessment method [8]
0
0
SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, & baseline value and modified baseline observation carried forward (mBOCF) imputation method.
Query!
Timepoint [8]
0
0
Baseline, Week 12
Query!
Secondary outcome [9]
0
0
Change From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS)
Query!
Assessment method [9]
0
0
SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the MCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, & baseline value and modified baseline observation carried forward (mBOCF) imputation method.
Query!
Timepoint [9]
0
0
Baseline, Week 12
Query!
Secondary outcome [10]
0
0
Change From Baseline in Genital Psoriasis Symptom Scale (GPSS) Total Score and Individual Items
Query!
Assessment method [10]
0
0
GPSS is a participant's-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (no severity) and 10 (worst imaginable severity). total score ranges from 0 (no severity) - 80 (worst imaginable severity) LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
Query!
Timepoint [10]
0
0
Baseline, Week 12
Query!
Secondary outcome [11]
0
0
Number of Participants Achieving sPGA of Genitalia (0,1) at Week 12 by Treatment-Emergent Anti-Drug Antibody (TE-ADA) Status and by Neutralizing Antibody (NAb) Status
Query!
Assessment method [11]
0
0
sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe.
sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.
Query!
Timepoint [11]
0
0
Week 12
Query!
Eligibility
Key inclusion criteria
- Have chronic plaque psoriasis based on a diagnosis of chronic plaque psoriasis for at
least 6 months before baseline.
- Have moderate-to-severe psoriasis in the genital area at screening and baseline.
- Have plaque psoriasis in a nongenital area at screening and baseline.
- Have failed to respond to, or are intolerant of, at least 1 topical therapy used for
treatment of psoriasis affecting the genital area.
- Must agree to use reliable method of birth control, which could include abstinence,
during the study and for at least 12 weeks following the last dose of study drug.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pustular, erythrodermic, and/or guttate forms of psoriasis.
- History of drug-induced psoriasis.
- Have recently received certain treatments for psoriasis (in particular, within the
past 4 weeks but the restriction can go up to 12 months for some treatments).
- Have ever received treatment with ixekizumab, secukinumab, brodalumab, or another drug
with a similar mode of action.
- Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks
prior to baseline and during the study.
- Are currently enrolled in any other clinical trial involving an investigational
product.
- Serious disorder or illness other than plaque psoriasis.
- Active or history of malignant disease within 5 years prior to baseline.
- Serious infection within the last 3 months.
- Have received a live vaccine within 3 months of baseline or plan to do so during the
study.
- Have received a vaccination with Bacillus Calmette-Guérin (BCG) within the past year.
- Pregnant or breastfeeding (lactating) women.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
21/02/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
149
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Carlton
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Darlinghurst
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
5073 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [3]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Oregon
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Rhode Island
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Utah
Query!
Country [10]
0
0
Austria
Query!
State/province [10]
0
0
Graz
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Wien
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Brussels
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Gent
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
London
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Markham
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Montreal
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
Quebec
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Surrey
Query!
Country [19]
0
0
Netherlands
Query!
State/province [19]
0
0
Bergen op Zoom
Query!
Country [20]
0
0
Netherlands
Query!
State/province [20]
0
0
Breda
Query!
Country [21]
0
0
Puerto Rico
Query!
State/province [21]
0
0
San Juan
Query!
Country [22]
0
0
Turkey
Query!
State/province [22]
0
0
Bursa
Query!
Country [23]
0
0
Turkey
Query!
State/province [23]
0
0
Gaziantep
Query!
Country [24]
0
0
Turkey
Query!
State/province [24]
0
0
Istanbul
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug
ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02718898
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02718898
Download to PDF